Evotec and BMS enter license agreement within existing neuroscience partnership

11 July 2023

US pharma major Bristol Myers Squibb (NYSE: BMY) has exercised its option to enter into an exclusive global license agreement with German drug discovery company Evotec (EVT: Xetra).

This license covers selected late-stage discovery programs that were developed and progressed within the neurodegeneration-focused collaboration, which the companies originally entered into in 2016.

"We are confident that the strong collaboration of the experienced teams at Evotec and BMS will make novel innovative treatment options available to patients"The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK